TOP > 外国特許検索 > IGA-BINDING PEPTIDE AND IGA PURIFICATION USING SAME

IGA-BINDING PEPTIDE AND IGA PURIFICATION USING SAME

外国特許コード F120006808
整理番号 S2010-0824-C0
掲載日 2012年7月3日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP061906
国際公開番号 WO 2011148952
国際出願日 平成23年5月24日(2011.5.24)
国際公開日 平成23年12月1日(2011.12.1)
優先権データ
  • 特願2010-118508 (2010.5.24) JP
発明の名称 (英語) IGA-BINDING PEPTIDE AND IGA PURIFICATION USING SAME
発明の概要(英語) Disclosed is a peptide which is characterized by comprising an amino acid sequence that is represented by (X1-3)-C-(X8-10)-C-(X1-3) (wherein each X independently represents an arbitrary amino acid residue other than cysteine and C represents a cysteine residue) and consists of 12-18 amino acid residues. The peptide is also characterized by being capable of binding to human IgA. Also disclosed is a method for assaying or purifying human IgA using the peptide.
従来技術、競合技術の概要(英語) BACKGROUND ART
(IgA) immunoglobulin A is, essential in the mucosal immunity as well as antibody, immunoglobulin g (IgG) present in the blood subsequent to predominant antibody class and 2, which operates on a bacteria and virus defense against infection. Is IgA, IgA dimer structure (sIgA) secreted IgA (mIgA) and monomer structure is present. Is sIgA, through Joining chain(J-chain) SS bond has a dimeric structure, is secreted into the mucus, many of the mIgA, exists in blood. In addition, is IgA, 2 of the hinge region of different lengths can be the main types of sub-type, there are IgA2 and IgA1, IgA2 Pro-rich region in the absence of 13 residues. The function of the directed to a pharmaceutical IgA, from their importance in the immune infection, in the development of mucosal vaccine have been focused (non-patent document 1 and 2), IgA is in the blood, particularly neutrophils ADCC is support by the cancer cells have been reported (non-patent document 3 and 4) from, for the treatment of cancer and autoimmune diseases that its clinical application is expanded in the same manner as in the format of a IgG antibody pharmaceuticals, also IgA antibody pharmaceuticals that target the cancer (non-patent document 5) as expected.
However, the factors for inhibiting the development of a medicament to IgA as one, such as IgG affinity columns A/g protein in the manufacture of industrial, pharmaceutical scale can be supported in a purification method and has not been established. Conventional, as are several methods of IgA purification methods have been reported (non-patent document 6). For example, IgA1 recognizes a sugar chain specific lectin (non-patent document 7) or a mimetic thereof Protein A Jackalin synthetic ligands (non-patent document 8) in TG19318 by the reported methods of purification IgA is, they are a problem in a binding capacity and specificity is a limitation in use. In addition, derived from a bacterium Streptococcus (non-patent document 9) surface protein from a member of the M protein family, was found IgA binding protein (non-patent document 10, patent document 1 and 11), such as IgG interaction with protein in the serum of other (non-patent document 12) or the like becomes a problem and, used as an affinity ligand specific IgA is there is a failure. On the other hand, Sandin et al., 48 residues in this Streptococcal Sir22 (M22) protein extracts QCRPSKGRKRGFCW (Streptococcal IgA-binding peptide, Sap), via Cys SS bond by dimerization, affinity than the original Sir22 protein (Kd value 3-4 nm) is somewhat inferior to the of the, a relatively high affinity (Kd value 20 nm) reported affinity ligands for purification of IgA (non-patent document 13, patent document 2). The ligand is in practice, of the bound Fc IgA, sIgA, both purification mIgA, antigen-specific IgA1 and further, application to the detection of a monoclonal antibody IgA2 was also possible.
IgA binding protein in the same manner as described above, by the present inventors also IgG IgG binding peptides have been developed (patent document 3).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KAGOSHIMA UNIVERSITY
  • OTSUKA CHEMICAL CO., LTD.
  • 発明者(英語)
  • ITO Yuji
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close